Mysimba Weight Loss Tablets

Mysimba is a weight loss treatment solution for anyone over the age of 18 who has a body mass index (BMI) of over 30 (which indicates obesity). If you have a BMI over 27 and suffer from co-morbidities such as type 2 diabetes or controlled hypertension then Mysimba could be the right weight loss medication for you to take.

A combination of naltrexone hydrochloride and bupropion hydrochloride, Mysimba has been developed to help people who want to lose weight by helping the brain to regulate your appetite and change the feelings you may have when eating food.

Mysimba has been shown to help people lose an average of 5% of their total body weight after 16 weeks, compared to 1% without using the medicine, when taken with a reduced calorie diet and increased exercise.

Mysimba can also help you to reduce triglycerides and LDL (bad) cholesterol. Diabetics taking Mysimba also noted improvements in their blood sugar control.

Mysimba is a tablet which can be taken with or without food. For the first week you take 1 tablet each morning. During the second week you take one tablet in the morning and 1 tablet in the evening. During the third week the dose is 2 tablets in the morning and 1 tablet in the evening. In the fourth week you should be taking 2 tablets both in the morning and in the evening.

Mysimba can cause side effects in some patients.

The most common side effects are:

Insomnia

Restlessness

Anxiety

Headache

Disturbance in concentration

Dizziness

Hot flushes

Palpatations

Constipation

Nausea

Muscular pain

If you do experience side effects while taking Mysimba, please report them to your doctor.

Whilst taking Mysimba, you should have your blood pressure regularly checked.

Week 1: One tablet once a day in the morning

Week 2: One tablet twice a day, one in the morning and one in the evening

Week 3: Three tablets every day, two in the morning and one in the evening

Week 4 and onward: Two tablets twice a day, two in the morning and two in the evening

• Patients between 18 and 65 years of age. • Patients with a BMI of 30 kg/m2 or greater in which a supervised diet and exercise fail to achieve a realistic reduction in weight.
• Patients with a BMI of 27 kg/m² or greater patient with risk factors such as sleep apnoea, type 2 diabetes mellitus, controlled hypertension or dyslipidemia.
• Patients who have unsuccessfully tried to manage their weight by altering their diet and increasing physical activity.
• Patients who do not want to

• Patients with hypersensitivity to active substance(s) or to any of the excipients (See section 6.1 of the SPC).

• Patients under the age of 18 years or over 65 years of age.

• Valid consent has not been gained.

• Patients with mild to severe renal impairment.

• Patients with mild to severe hepatic impairment.

• Patients with uncontrolled hypertension.
• Patients with type 1 diabetes mellitus.

• Patients undergoing acute withdrawal from alcohol, benzodiazepine or other sedatives.

• Patients currently dependent on chronic opioids or opiate agonists (e.g., methadone), or patients in acute opiate withdrawal.

• Patients with a current seizure disorder, history of seizures or known central nervous system (CNS) tumour.

• Patients receiving chronic opiate therapy.

• Patients with an addiction to cocaine or other stimulants.

• Patients with a history of bipolar disorder.

• Patients with depression, generalized anxiety disorder, psychosis, schizophrenia, suicide attempts, suicidal thoughts, self-endangering behaviour or any other psychiatric disorder.

• Patients with obesity secondary to endocrinological or eating disorders or to treatment with medicinal products that may cause weight gain.

• Patients with active coronary artery disease (e.g., ongoing angina) or history of myocardial infarction.

• Patients with brain or nervous system disorders.

• Patients with a current or previous diagnosis of bulimia or anorexia nervosa.

• Patients receiving any concomitant treatment containing bupropion or naltrexone.

• Patients receiving concomitant administration of monoamine oxidase inhibitors (MAOI).
• Patients with a history of cerebrovascular disease.
• Patients with a history of suicidal behaviour.
• Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
• Concurrent administration with opiate containing medicines.
• Women not using an effective method of contraception (e.g condoms). Progesterone only contraceptive pills are not considered effective contraception.
• Patients who require specialist management.
Temporary Exclusion

• Known or suspected pregnancy.

• Breast-feeding women.

• Treatment with a MAOI within the last 14 days.